CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Clinical trials for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) trials appear
Sign up with your email to follow new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to outperform standard lung cancer therapy
Disease control Recruiting nowThis study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer that has spread. About 1,410 participants will be randomly ass…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for lung cancer: combo therapy aims to outsmart tumors
Disease control Recruiting nowThis study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 adults with stage 3 or 4 lung cancer will t…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 19, 2026 12:01 UTC